Replies to post #246663 on Biotech Values

[DewDiligence]

Re: SGEN-related comments from PFE’s 1Q23 CC

PFE did say some things about SGEN data already in the public domain:

• PFE expects Adcetris to get an updated label in first-line HL incorporating the recently announced OS data from the ECHELON-1 trial (https://investor.seagen.com/press-releases/news-details/2022/ADCETRIS-Combination-Significantly-Improves-Overall-Survival-in-Newly-Diagnosed-Patients-with-Advanced-Hodgkin-Lymphoma/default.aspx ).

• PFE is “excited” about the recent FDA accelerated approval of Padcev with Keytruda in cisplatin-ineligible patients in urothelial cancer (https://investor.seagen.com/press-releases/news-details/2023/FDA-Grants-Accelerated-Approval-for-PADCEV-enfortumab-vedotin-ejfv-with-KEYTRUDA-pembrolizumab-for-First-Line-Treatment-of-Locally-Advanced-or-Metastatic-Urothelial-Cancer/default.aspx ), and is looking forward to results from the phase-3 trial for cisplatin-eligible patents, which has an expected completion date of Nov 2023 (https://www.clinicaltrials.gov/ct2/show/NCT04223856 ).

PFE has not seen any non-public data from the phase-3 trial of Adcetris vs Opdivo in first-line HL—the trial where SGEN is presenting some PFS data at the upcoming ASCO (https://www.clinicaltrials.gov/ct2/show/NCT03907488 ).

Whether PFE has seen non-public SGEN data from any trial is unclear insofar as PFE did not confirm or deny.